

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 88973

Title: Liver decompensation after rapid weight loss from semaglutide in a patient with non-alcoholic steatohepatitis -associated cirrhosis

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02353723

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Professor

Reviewer's Country/Territory: Italy

Author's Country/Territory: Australia

Manuscript submission date: 2023-10-17

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-10-17 11:07

Reviewer performed review: 2023-10-21 17:55

Review time: 4 Days and 6 Hours

Scientific quality	<input checked="" type="radio"/> Grade A: Excellent <input type="radio"/> Grade B: Very good <input type="radio"/> Grade C: Good <input type="radio"/> Grade D: Fair <input type="radio"/> Grade E: Do not publish
Novelty of this manuscript	<input checked="" type="radio"/> Grade A: Excellent <input type="radio"/> Grade B: Good <input type="radio"/> Grade C: Fair <input type="radio"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input checked="" type="radio"/> Grade A: Excellent <input type="radio"/> Grade B: Good <input type="radio"/> Grade C: Fair <input type="radio"/> Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The manuscript of Peverelle et al. is clear and organized and the data presented are relevant for clinical practice. The language and grammar are accurate and appropriate, with a title that reflects the main subject of the manuscript. The abstract summarizes the work described in the manuscript, and the keywords are appropriate. The findings are new and relevant for clinical practice. References are appropriate and the figure is of good quality with correct and explicative labeling. In the discussion, I would suggest adding a comment on the fact that despite the patient's weight substantially not changing after the interruption of semaglutide, liver function continued to deteriorate in the successive 6 months. Moreover, in the parallelism with bariatric surgery regarding liver decompensation, it should be underlined that in these patients decompensation occurred later and their weight loss reached 110%.

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 88973

Title: Liver decompensation after rapid weight loss from semaglutide in a patient with non-alcoholic steatohepatitis -associated cirrhosis

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04025443

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Doctor, Senior Researcher

Reviewer's Country/Territory: Russia

Author's Country/Territory: Australia

Manuscript submission date: 2023-10-17

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-10-26 02:49

Reviewer performed review: 2023-10-29 19:44

Review time: 3 Days and 16 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Dear colleagues! I read with interest your Letter to the Editor, that refers recently published in WJG systematic review by K. Zhu et al on the efficacy and safety of semaglutide in non-alcoholic fatty liver disease. The letter may bring new to the field and could be interesting to the readers. The manuscript requires appropriate revision according to the Journal's recommendations on research methods and reporting. I have a few comments. Please, check the initial MELD-Na score - my calculation lead to the number of points 23, in contrast to provided in the Letter (22). There is a need for better description of the treatment before decompensation occurred (whether all recommendation were followed by the patient) and after it. Please, list the concomitant medications. What is an "alcohol misuse"? Is it an "alcohol abuse"? Please, add the certain information on the use of the alcohol by the patient, as alcohol intake may lead to Moderate Drug Interaction with semaglutide. Please, explain the misuse of semaglutide - per international prescribing information initial dose should be 0.25 milligrams (mg) injected under the skin (SC) once a week for 4 weeks and 0.5 mg SC once a week on weeks 5 through 8. Please, describe the weight change before the



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

decompensation event. As GLP-1 agonists may delay gastric emptying, which may impact the absorption of concomitantly administered oral medications, this should be mentioned in the discussion as standard treatment prescribed for liver cirrhosis could be of lower efficacy in this case. The last phrase is not enough clear. Namely, what is a "rapid weight loss" (in kg/month)? Should the maximal dose of the medication be lower in case of liver cirrhosis? Please, add that strict following of the prescribing information and the initial dose escalation schedule are the must, especially in such a vulnerable group of patients as subjects with liver cirrhosis.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 88973

Title: Liver decompensation after rapid weight loss from semaglutide in a patient with non-alcoholic steatohepatitis -associated cirrhosis

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04025443

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Doctor, Senior Researcher

Reviewer's Country/Territory: Russia

Author's Country/Territory: Australia

Manuscript submission date: 2023-10-17

Reviewer chosen by: Cong Lin

Reviewer accepted review: 2023-11-10 10:03

Reviewer performed review: 2023-11-10 10:10

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Dear colleagues! Congratulations with the great job done! All my questions are answered. The paper has been improved and may be published.